Clinical Trial Update: Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on SPD503 for treating ADHD in children 6-17, reporting safety, tolerability, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPD503

Snippet

Sponsor: Shire | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 2 | Status: COMPLETED | Results posted: 2009-10-14